Literature DB >> 18376314

Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct.

Nida S Awadallah1, Kenneth R Shroyer, Daniel A Langer, Kathleen C Torkko, Yang K Chen, Joel S Bentz, Jackie Papkoff, Wenhui Liu, S Russell Nash, Raj J Shah.   

Abstract

OBJECTIVES: This study compared p53 expression with B7-H4, a novel cancer biomarker, in pancreatic ductal adenocarcinoma (PDA) resection specimens and in a pilot series of endoscopic ultrasound-guided fine-needle aspirations (EUS-FNAs).
METHODS: B7-H4 and p53 expression were evaluated by immunoperoxidase methods in 36 PDA and 15 EUS-FNA specimens and were scored for intensity and proportion of positive cells; cases were then assigned a final sum score.
RESULTS: B7-H4 was detected in 33 (92%) of 36 PDA sections, 8 (89%) of 9 cytologically positive EUS-FNAs, and 1 (20%) of 5 cytologically negative EUS-FNAs. p53 was detected in 30 (83%) of 36 PDA sections, 4 (44%) of 9 cytologically positive EUS-FNAs, and 1 (20%) of 5 cytologically negative cases. One EUS-FNA case that was cytologically atypical but not diagnostic of malignancy expressed B7-H4 and p53. Some benign tissue components (intercalated cells/ducts, main pancreatic ducts, and acinar cells) were also positive for B7-H4 and/or p53. Overall expression of B7-H4 in benign tissues, however, was relatively low compared with that seen in most carcinoma cases.
CONCLUSIONS: B7-H4 was expressed more often in PDA than was p53. Despite potentially problematic expression in benign/normal cells, the 2 markers target different cellular components and demonstrate potential diagnostic use for detection of PDA in resected and EUS-FNA specimens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18376314     DOI: 10.1097/MPA.0b013e318150e4e0

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  30 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

Review 2.  T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.

Authors:  Yael S Barach; Jun Sik Lee; Xingxing Zang
Journal:  Trends Mol Med       Date:  2011-01       Impact factor: 11.951

3.  B7-H4 downregulation induces mitochondrial dysfunction and enhances doxorubicin sensitivity via the cAMP/CREB/PGC1-α signaling pathway in HeLa cells.

Authors:  Hyoung Kyu Kim; In-Sung Song; Sun Young Lee; Seung Hun Jeong; Sung Ryul Lee; Hye Jin Heo; Vu Thi Thu; Nari Kim; Kyung Soo Ko; Byoung Doo Rhee; Dae Hun Jeong; Young Nam Kim; Jin Han
Journal:  Pflugers Arch       Date:  2014-12       Impact factor: 3.657

4.  Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer.

Authors:  Takaaki Arigami; Yoshikazu Uenosono; Sumiya Ishigami; Takahiko Hagihara; Naoto Haraguchi; Shoji Natsugoe
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

5.  Prognostic value of soluble H7-B4 in pleural effusion associated with lung cancer.

Authors:  Chun-Hua Xu; Lan Cao; Xiu-Wei Zhang; Jun Yan; Li-Ke Yu
Journal:  Tumour Biol       Date:  2015-02-01

6.  Intracellular B7-H4 suppresses bile duct epithelial cell apoptosis in human primary biliary cirrhosis.

Authors:  Yongwen Chen; Guoning Guo; Sheng Guo; Shinji Shimoda; Kenneth R Shroyer; Yuyu Tang; Yuzhang Wu
Journal:  Inflammation       Date:  2011-12       Impact factor: 4.092

7.  Increased B7H4 tissue expression correlates with high CA19.9 serum levels and a worse prognosis of pancreatic adenocarcinoma.

Authors:  Anastasia Tsiaousidou; A K Tsaroucha; M Lambropoulou; M Pitiakoudis; A Polychronidis; E Chatzitheoklitos; K Romanidis; C Simopoulos
Journal:  Clin Exp Med       Date:  2015-04-30       Impact factor: 3.984

Review 8.  The complex role of B7 molecules in tumor immunology.

Authors:  Barbara Seliger; Francesco M Marincola; Soldano Ferrone; Hinrich Abken
Journal:  Trends Mol Med       Date:  2008-11-03       Impact factor: 11.951

Review 9.  Combination cancer immunotherapy and new immunomodulatory targets.

Authors:  Kathleen M Mahoney; Paul D Rennert; Gordon J Freeman
Journal:  Nat Rev Drug Discov       Date:  2015-08       Impact factor: 84.694

10.  B7-H3 and B7-H4 are independent predictors of a poor prognosis in patients with pancreatic cancer.

Authors:  Hong Xu; Xiaoling Chen; Min Tao; Kai Chen; Chen Chen; Gang Xu; Wei Li; Suxu Yuan; Yixiang Mao
Journal:  Oncol Lett       Date:  2016-01-19       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.